Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Venous smooth muscle adrenergic receptors are G protein-coupled receptors located on the smooth muscle cells of venous blood vessels, particularly mediating sympathetic nervous system signals[1][2]. They are represented primarily by alpha-1 (causing vasoconstriction upon activation), alpha-2 (whose effects vary depending on location—vasoconstriction peripherally but presynaptic inhibition leading to vasodilation systemically), and beta-2 (causing vasodilation)[1][2]. These receptors are targets for a variety of cardiovascular drugs that alter venous tone to influence systemic blood pressure and venous return[1][4].
Alpha-1 antagonist: blocks vasoconstriction, promotes vasodilation and lowers blood pressure; Alpha-1 agonist: induces vasoconstriction, increases blood pressure; Alpha-2 agonist: presynaptic inhibition of sympathetic tone (vasodilation dominates), but can cause post-synaptic vasoconstriction in blood vessels; Beta-2 agonist: mediates smooth muscle relaxation and vasodilation, mainly via cAMP signaling
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adrenergic receptor (venous smooth muscle) (null).